Sripal Bangalore on Muck Rack

Sripal Bangalore

New York, United States
As seen in: Wiley Online Library, The BMJ, JAMA: Journal of the American Medical Association, JAMA Cardiology, Medscape, The New England Journal of Medicine, The Lancet, AHA/ASA Journals, Annals of Internal Medicine, Healio and
Director Complex Coronary Intervention, Prof of Medicine, NYU School of Medicine, #radialfirst, #CTO, #MCS, #CHIP, #ZerocontrastPCI, #PERT, #ECMO
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sripal

Contact Sripal, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention : A Systematic Review and Meta-Analysis

|
By M. Maqsood, Frederick Feit, Upendra Kaul, Sunil V. Rao, Daniele Giacoppo, Adnan Kastrati, Sripal Bangalore
| JAMA Cardiology
Key Points Question Which of the oral P2Y purinergic receptor 12 (P2Y12) inhibitors provides the optimal efficacy and safety in patients after percutaneous coronary intervention (PCI)? Findings In this systematic review and meta-analysis, there was a lower risk of major adverse cardiovascular events (MACE) with prasugrel compared to clopidogrel and compared to ticagrelor driven by lower myocardial infarction and lower stent thrombosis.
Open in Who Shared Issue with article?

Drug-Eluting Stent, Drug-Coated Balloon, or Conventional Angioplasty for In-Stent Coronary Restenosis: An Updated Meta-Analysis of Randomized Trials

|
By M. Maqsood, Robert Zhang, Sripal Bangalore
| Journal of Invasive Cardiology Verified
© 2026 HMP Global. All Rights Reserved. Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the Journal of Invasive Cardiology or HMP Global, their employees, and affiliates. J INVASIVE CARDIOL 2026. doi:10.25270/jic/26.00028. Epub April 15, 2026. Objectives.
Open in Who Shared Issue with article?

Ticagrelor vs Prasugrel in Patients With Diabetes and Multivessel Coronary Artery Disease: The TUXEDO-2 Randomized Clinical Trial

|
By Sripal Bangalore
| JAMA Cardiology
Ticagrelor vs Prasugrel in Patients With Diabetes and Multivessel Coronary Artery Disease: The TUXEDO-2 Randomized Clinical Trial Key Points Question Is ticagrelor noninferior to prasugrel after percutaneous coronary intervention in patients with diabetes and multivessel disease?
Open in Who Shared View Duplicates (2) Issue with article?
See all 77 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified